Omid Hamid

Omid Hamid

Oncology
11818 Wilshire Blvd
Los Angeles, CA 90025

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 217 publications

Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies.

Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies.

Journal: Journal for immunotherapy of cancer
Published: July 07, 2026

Tryptophan degradation by intestinal Bacteroides induces anti-tumor immunity and limits melanoma growth.

Tryptophan degradation by intestinal Bacteroides induces anti-tumor immunity and limits melanoma growth.

Journal: bioRxiv : the preprint server for biology
Published: May 25, 2026

Tebentafusp (IMCgp100), a first in class immune-mobilizing monoclonal T-cell receptors against cancer (ImmTAC) for HLA-A*02:01 positive uveal melanoma: Product review.

Tebentafusp (IMCgp100), a first in class immune-mobilizing monoclonal T-cell receptors against cancer (ImmTAC) for HLA-A*02:01 positive uveal melanoma: Product review.

Journal: Human vaccines & immunotherapeutics
Published: May 21, 2026

Five-year survival with tebentafusp in metastatic uveal melanoma.

Five-year survival with tebentafusp in metastatic uveal melanoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 02, 2026

Phase 1/2 study of INCAGN01876, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, plus immunotherapy for advanced cancers.

Phase 1/2 study of INCAGN01876, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, plus immunotherapy for advanced cancers.

Journal: The oncologist
Published: January 21, 2026

Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients.

Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients.

Journal: Biomarker research
Published: January 09, 2026

Safety and efficacy of intratumoral MEDI1191, an IL-12 mRNA lipid nanoparticle, plus intravenous durvalumab in patients with advanced solid tumors: a first-in-human study.

Safety and efficacy of intratumoral MEDI1191, an IL-12 mRNA lipid nanoparticle, plus intravenous durvalumab in patients with advanced solid tumors: a first-in-human study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 07, 2026

Pre-vaccine immune profiling in cancer patients identifies correlates of COVID-19 vaccine responses.

Pre-vaccine immune profiling in cancer patients identifies correlates of COVID-19 vaccine responses.

Journal: Human vaccines & immunotherapeutics
Published: December 16, 2025

A Phase 1 First-Time-in-Human, Open-Label Study of Nelistotug Administered to Patients with Advanced Solid Tumors.

A Phase 1 First-Time-in-Human, Open-Label Study of Nelistotug Administered to Patients with Advanced Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 27, 2025

Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies.

Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies.

Journal: Cancer
Published: November 04, 2025

IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.

IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 31, 2025

Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma.

Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma.

Journal: BMC cancer
Published: September 30, 2025
Showing 1-12 of 217

Last Updated: 09/26/2026